local_hospital

Azienda USL Toscana Centro

Address
lock Available on a paid plan

Immune System Diseases

At Azienda USL Toscana Centro, clinical research in immune system diseases focuses on conditions such as dermatomyositis, polymyositis, and cutaneous lupus erythematosus. These studies are designed to evaluate new treatment options and better understand safety, tolerability, and symptom improvement in people living with complex inflammatory disorders.

  • Trials exploring new therapies for dermatomyositis and polymyositis
  • Research in subacute and chronic cutaneous lupus erythematosus
  • Studies assessing treatment safety, long-term tolerability, and clinical benefit

This area reflects a strong interest in improving care for autoimmune conditions that can affect both skin and muscles.

Skin and Connective Tissue Diseases

The dermatology research program at this Florence site includes several studies in skin and connective tissue diseases, with a particular emphasis on atopic dermatitis, generalized pustular psoriasis, and hidradenitis suppurativa. The trials aim to test whether new treatments can reduce symptoms, control flares, and improve day-to-day skin health.

  • Studies in moderate to severe atopic dermatitis evaluating symptom relief and disease control
  • Research on generalized pustular psoriasis to help manage repeated flare-ups
  • Trials in hidradenitis suppurativa focused on effectiveness after prior treatment failure

These investigations support the search for better therapies in chronic and often difficult-to-treat dermatologic conditions.

Musculoskeletal Diseases

Research in musculoskeletal diseases at Azienda USL Toscana Centro overlaps with inflammatory conditions that can involve both the muscles and the skin. The clinical trials in this field are mainly aimed at improving treatment response and confirming the safety of emerging therapies for patients with severe, persistent disease.

  • Studies involving dermatomyositis and polymyositis
  • Evaluation of therapies intended to improve disease activity and patient outcomes
  • Ongoing work to expand options for people with limited current treatment choices

This therapeutic area highlights the site’s role in advancing care for inflammatory disorders that affect movement, strength, and overall quality of life.

Alopecia Areata and Hair Loss Research

The site also participates in studies on alopecia areata, including severe forms affecting both adults and adolescents. These trials are focused on testing new medicines that may help restore hair growth, reduce disease activity, and provide longer-term disease control.

  • Trials in severe alopecia areata assessing treatment effectiveness
  • Research aimed at improving long-term safety and sustained response
  • Studies involving both adult and adolescent participants

This work adds an important hair and scalp disease focus to the broader dermatology portfolio at the Dermatology Department.

Site Overview

assignment
8
connected trials
corporate_fare
7
sponsors
science
12
IMPs

Activity Indicator

Last 6 months

1
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
8
Total trials linked
Active
trending_upGrowing+100%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 6 therapeutic areas and 12 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
2
Sponsors (total)
7
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
8
Outperforms 65% of sites
public
Therapeutic diversity
6areas
Outperforms 75% of sites
groups
Sponsor diversity
7sponsors
Outperforms 66% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Azienda USL Toscana Centro

lock Showing 1 of 8 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A NephropathyOtsuka Pharmaceutical Development & Commercialization Inc.Phase IIINot RecruitingNov 2022May 2026

IMP list

lock Showing 1 of 12 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Upadacitinib2Unknown2023-10-262024-06-17

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.